Ohio State Navbar

Research

Research


                

Research

Ohio State University Medical Center’s Diabetes and Metabolism Research Center is committed to conducting clinical trials and basic research that translate to managing, preventing and curing diabetes. Our patients have access to participate in state-of-the-art clinical trials for new drugs and technologies.

The Diabetes and Metabolism Research Center collaborates with several divisions to foster a team approach in innovative procedures such as islet cell, pancreas and kidney transplantation. In 2008, OSU Medical Center conducted the first humanislet cell transplant in Ohio, and is one of few centers in the nation to offer this new and innovativetreatment option.

The vision of The Ohio State University Medical Center’s Diabetes and Metabolism Research Center is “to create a world without diabetes.” Our dedicated team of physicians and researchers are committed to making this vision a reality by focusing on personalized health care to provide better outcomes in research, patient care and education.

Islet Cell Research:

Human and Non–Human Primate Islet Cell Transplantation (ICT):

The ability to perform ICT at Ohio State epitomizes advancement in the care of patients with severe beta cell pancreatic diseases. The ICT program in both human and non-human primates has been a joint venture between the Diabetes and Metabolism Research Center and the Comprehensive Transplantation Center at Ohio State. Dr. Wang, a researcher with the Division of Endocrinology, Diabetes and Metabolism and the Diabetes and Metabolism Research Center, set up an entire lab devoted to the basic research of islet cell biology. The lab is wholly focused on clinical research in the related field of diabetes study which Dr. Wang had initially started at the HHMI lab in the University of Chicago in November 2006.

Improving beta cell function in young Mexican American (MA) young women with prediabetes:

This R01 funded investigation, led by Willa Hsueh, MD, Principle Investigator, targets serious health disparities in metabolic disease in a highly vulnerable, rapidly growing population, testing novel gender- and culturally-focused intervention strategies lead by Evangelina Villagomez, PhD, Co-Investigator in Houston, TX. The study team includes, Kathleen Wyne, MD, PhD and David Bradley, MD. The primary endpoint will be improved pancreatic function [Beta (β)]-cell function (Acute Insulin Response/g, deposition index) defined by frequently sampled intravenous glucose tolerance testing. Secondary endpoints include changes in β-cell markers (C-peptide, insulinogenic index (IGI), glucagon); novel plasma biomarkers that predict diabetes and inflammation; and metabolic syndrome components.

Most genes that have been identified for diabetes-related traits influence β-cell growth, differentiation and function. Co-Investigators from UCLA, Drs. Rotter, Chen, Goodarzi, will assist this team in selecting a group of single nucleotide polymorphisms (SNPs) on the Metabochip to correlate variations in such Type 2 Diabetes genes/loci with insulin responses and other phenotypes in liraglutide-treated subjects.

Our objective is to combine an intensive lifestyle intervention approach (LSI)), in combination with a Glucagon Like Peptide-1 agonist to improve β-cell function and prevent the downward spiral of metabolic disease in an MA community plagued by poverty. We are targeting MA women because they have the highest rates of metabolic syndrome in the US compared to men or other ethnic groups.

Inpatient Diabetes Research:

Glucose Fluctuations and Co morbidities in Patients with Diabetes

Recent large multicenter inpatient and outpatient studies have highlighted the potential benefits as well as potential dangers of tight blood sugar control. Such studies have prompted calls for safer, more individualized approaches to diabetes therapy, particularly in patients with end organ complications. In particular, measures to stabilize glucose fluctuations may have the potential to preserve or enhance the benefits of glycemic control while reducing the risks for hypoglycemia. Several preliminary studies indicate that extreme fluctuations in glucose (glucose variability) are associated with cellular dysfunction, heart rhythm abnormalities, and death, even if more conventional assessments of “average” glucose are acceptable.

Research initiatives include retrospective analysis of quality control measures as well as prospective studies, including the study of optimal methods of implementing insulin therapy in the hospital setting and the utility of continuous subcutaneous glucose monitoring technology.